lukas scheibler  acucela inc  zoominfocom insider trading  scheibler lukas  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  scheibler lukas select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm kubota pharmaceutical holdings co ltd m scheibler lukasevp of research  development    direct view sale  pm acucela inc m scheibler lukasevp of research  development    direct view sale  pm acucela inc m scheibler lukasevp of research  development    direct view sale  pm acucela inc m scheibler lukasevp of research  development    direct view sale  pm acucela inc m scheibler lukasevp of research  development    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing exercise  pm nana kubota pharmaceutical holdings co ltd m scheibler lukasevp of research  development   direct view exercise  pm na kubota pharmaceutical holdings co ltd m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view tax withholding  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view exercise  pm nana acucela inc m scheibler lukasevp of research  development   direct view option award  pm na acucela inc m scheibler lukasevp of research  development   direct view option award  pm na acucela inc m scheibler lukasevp of research  development   direct view option award  pm na acucela inc m scheibler lukasevp of translational medicine   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  jim scheibler  washington biathlon association  zoominfocom lukas scheibler phd executive profile  biography  bloomberg health care sector » pharmaceuticals industry »  kubota pharmaceutical holdin tokyo stock exchange  on other exchanges symbolexchange  is not on other exchanges snapshotnewschartsfinancialsearningspeople transactions overviewboard memberscommittees executive profile lukas scheibler phdexecutive vice president of research  development  acucela inckubota pharmaceutical holdings co ltdagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background dr lukas scheibler phd serves as an executive vice president of research and development at acucela inc dr scheibler served as executive vice president of translational medicine at acucela inc august   at acucela dr scheibler manages the translation of preclinical research into clinical development he plays a key role in acucela’s business development team manage its new projects before proof of concept to provide key dimensions of study protocols  and oversee its relationships with major academic sites and research institutions dr scheibler joined acucela after a year career in research and development business development and clinical trial management at novartis he started work at novartis headquarters in switzerland in  as manager of global drug regulatory affairs he worked since  at alcon a division of novartis and the world’s largest eye care company he served as a vice president in charge of alcon’s ideation and technology evaluation center before that he served as alcon’s vice president and global head of clinical trial management he served as vice president and global head of rd alliances at alcon from  to  dr scheibler received a master’s degree in chemistry from university of basel switzerland a phd in chemistry from university of lausanne switzerland and his postdoctoral training from harvard medical schoolread full background corporate headquarters yebisu garden place towertokyo  japanphone    fax     board members memberships there is no board members memberships data available education postdoctoral training harvard medical schoolmasters degree universität baselphd université de lausanne other affiliations harvard medical schooluniversität baseluniversité de lausanne annual compensation salarytotal annual compensation stock options all other compensationexercisable optionsunexercisable optionsunexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact kubota pharmaceutical holdin please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close acucela hires dr lukas scheibler as executive vice president of translational medicine  business wire acucela hires dr lukas scheibler as executive vice president of translational medicine dr scheibler joins company after  years at industryleading novartis august    pm eastern daylight time seattlebusiness wireacucela inc tokyo “acucela” or the “company” a clinicalstage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sightthreatening ophthalmic diseases announced today that it has hired dr lukas scheibler as executive vice president of translational medicine dr scheibler joins acucela after a year career in research and development business development and clinical trial management at novartis the world’s largest pharmaceutical company dr scheibler worked since  at alcon a division of novartis and the world’s largest eye care company he most recently was a vice president in charge of alcon’s ideation and technology evaluation center the company’s center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology before that he served as alcon’s vice president and global head of clinical trial management at acucela dr scheibler will manage the translation of preclinical research into clinical development he will play a key role in the company’s business development team manage the company’s new projects before proof of concept to provide key dimensions of study protocols and oversee the company’s relationships with major academic sites and research institutions the acucela board of directors appointed dr scheibler as executive vice president of translational medicine effective aug   at its aug  meeting in seattle “dr scheibler is one of the world’s leading experts in the research and development of treatments and cures for ophthalmic diseases” said ryo kubota md phd chairman president and ceo of acucela inc “he brings an international and industryleading pedigree that we welcome as acucela works toward its goal of becoming an international leader in the treatment of debilitating eye diseases” dr scheibler started work at novartis headquarters in switzerland in  as manager of global drug regulatory affairs while he served as vp and global head of rd alliances at alcon from  to  he played an important role as the company made several major acquisitions and deals including the purchase of lensx lasers for up to us  million esbatech for up to us  million and a research agreement with astrazeneca for exclusive access to the company’s ophthalmology compound library dr scheibler received a master’s degree in chemistry from university of basel switzerland a phd in chemistry from university of lausanne switzerland and his postdoctoral training from harvard medical school “this is such a promising and exciting time in acucela’s growth as a leader in ophthalmology and research and clinical development will be so critical to the company as it matures” dr scheibler said “we will be on the lookout for new opportunities and new avenues to be an innovator in the treatment of eye diseases i can’t wait to get started” about acucela inc acucela inc wwwacucelacom or wwwacucelajp is a clinicalstage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sightthreatening ophthalmic diseases which could impact millions of individuals worldwide acucela currently has the following codevelopment agreements with otsuka pharmaceutical co ltd emixustat hydrochloride its lead investigational drug candidate for geographic atrophy associated with dry agerelated macular degeneration based on acucela’s proprietary visual cycle modulation technology and opa an investigational compound originating from otsuka pharmaceutical for the treatment of ocular hypertension and glaucoma cautionary statements certain statements contained in this press release are forwardlooking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of  any statements contained in this press release that are not statements of historical fact may be deemed to be forwardlooking statements words such as “will” “believe” expect” “intend” “plan” and “should” as well as similar expressions are intended to identify forwardlooking statements these forwardlooking statements include acucela’s expectations regarding corporate development activities and the ultimate success of the enterprise these statements involve risks and uncertainties that could cause the company’s actual results to differ materially from those projected in forwardlooking statements including but not limited to the risk that our investigational product candidates will not demonstrate the expected benefits the willingness of our collaboration partner to continue to codevelop our investigational product candidates the risk of delays in our expected clinical trials the risk that new developments in the intensely competitive ophthalmic pharmaceutical market require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates and other risks and uncertainties inherent in the process of discovering and developing therapeutics that demonstrate safety and efficacy for a detailed discussion of these and other risk factors please refer to the company’s filings with the securities and exchange commission the “sec” which are available on the company’s investor relations web site httpiracucelacom and on the sec’s web site httpwwwsecgov contacts us mediaashley bachpacific public affairsashleypacificpubcomorjapan mediafor acucela inctomomi sukagawadirector investor relations and communicationinvestoracucelacom contacts us mediaashley bachpacific public affairsashleypacificpubcomorjapan mediafor acucela inctomomi sukagawadirector investor relations and communicationinvestoracucelacom search advanced news search advanced news search log in sign up eyewire today  acucela hires dr lukas scheibler as executive vice president of translational medicine home eyewiretv news events login username password home eyewiretv news events acucela hires dr lukas scheibler as executive vice president of translational medicine source acucela wednesday august    managementleadership  acucela acucela announced that it has hired lukas scheibler phd as executive vice president of translational medicine dr scheibler joins acucela after a year career in research and development business development and clinical trial management at novartis according to a company news release dr scheibler worked since  at alcon a division of novartis and the world’s largest eye care company he most recently was a vice president in charge of alcon’s ideation and technology evaluation center the company’s center of excellence in charge of identifying novel technologies that address unmet needs in ophthalmology before that he served as alcon’s vice president and global head of clinical trial management at acucela dr scheibler will manage the translation of preclinical research into clinical development he will play a key role in the company’s business development team manage the company’s new projects before proof of concept to provide key dimensions of study protocols and oversee the company’s relationships with major academic sites and research institutions         the acucela board of directors appointed dr scheibler as executive vice president of translational medicine effective aug   at its aug  meeting in seattle “dr scheibler is one of the world’s leading experts in the research and development of treatments and cures for ophthalmic diseases “ ryo kubota md phd chairman president and ceo of acucela said in the news release “he brings an international and industryleading pedigree that we welcome as acucela works toward its goal of becoming an international leader in the treatment of debilitating eye diseases”    dr scheibler started work at novartis headquarters in switzerland in  as manager of global drug regulatory affairs while he served as vice president and global head of rd alliances at alcon from  to  he played an important role as the company made several major acquisitions and deals including the purchase of lensx lasers for up to  million esbatech for up to  million and a research agreement with astrazeneca for exclusive access to the company’s ophthalmology compound library dr scheibler received a master’s degree in chemistry from university of basel switzerland a phd in chemistry from university of lausanne switzerland and his postdoctoral training from harvard medical school “this is such a promising and exciting time in acucela’s growth as a leader in ophthalmology and research and clinical development will be so critical to the company as it matures” dr scheibler said in the news release “we will be on the lookout for new opportunities and new avenues to be an innovator in the treatment of eye diseases i can’t wait to get started”   comments you must be logged in to leave a comment upcoming events   advanced refractive congress  oisasrs featured stories thursday july    fda approvalclearance product releases quantel medical quantel medical receives fda approval for easyret photocoagulator laser quantel medical announced that it has received approval from the fda for the easyret fully integrated nm yellow photocoagulator which is used to t… read the full story wednesday july    clinical trials earnings  financials amd ophthotech ophthotech expands focus with development for ophthalmic orphan diseases ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapie… read the full story monday july    product releases cenegermin eye drops for the treatment of neurotrophic keratitis receive european union approval dompe announced that the european commission has granted the marketing authorization of cenegermin eye drops for the treatment of moderate to severe n… read the full story friday july    dry eye medical studies tfos dews ii report published dry eye disease redefined the longawaited tear film  ocular surface society tfos dry eye workshop ii dews ii report was published on july   updating the defin… read the full story tuesday july    earnings  financials alcon latest novartis earnings show signs of a rebound at alcon as part of its second quarter earnings novartis reported that sales at its alcon unit accelerated in the second quarter novartis chief executive joe… read the full story news company news product news research meetings   events eyewiretv login acquisitions blindness clinical trials conferencesmeetings lawsuits earnings  financials fda approvalclearance glaucoma health care international approvals managementleadership medical studies miscellaneous optometry partnerships practice development product releases retina contact advertising about send a tip or event     bryn mawr communications llcall rights reserved lukas scheibler  executive vice president rd at acucela inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink lukas scheibler executive vice president rd at acucela inc overview in the news relationships paths education career history public holdings lukas scheibler executive vice president rd at acucela inc overview number of relationships this person is connected to  people in the news see more the seattle times september   acucela taps scheibler as executive vp of translational medicine relationships see details john gebhart chief financial officer at kubota pharmaceutical holdings co ltd ted danse chief business officer at acucela inc ryo kubota founder at acucela inc carol m pohlod directorcorporate communications at acucela inc roger e girard chief strategy officer at kubota pharmaceutical holdings co ltd jeffrey k gregory chief medical director at acucela inc kenzo ogiwara general manager at acucela inc brian ocallaghan senior positions uk at pfizer inc aki tobaru director at acucela inc dewey h blocker jr former chief financial officer secretary treasurer cao  vice president at acucela inc see  more listings with relsci professional start my free trial ➤ see  more paths to lukas scheibler lukas scheibler you connections via relationship science lukas scheibler sync your contacts to see how you can connect with lukas scheibler start my free trial ➤ see more educational background   university of basel the university of basel is the oldest university in switzerland founded upon the initiative of local citizens in  the university of basel is a modern and attractive center of teaching learning and research situated in the heart of basel the university of basel has been selfmanaged since  whilst remaining under the jurisdiction of the cantons of baselstadt and basellandschaft it provides committed individuals from all over the world a strong academic community and an inspiring work environment it employs nearly  people and its annual budget is around chf  million the university of basel is a classic university covering almost all fields of study from ancient studies to zoology the university of basel is a rather small university in european standards with around  students including  doctoral students as of  around  professors and  lecturers provide an excellent education and encourage independent thinking and responsible action the proportion of female students is   and rising  and one of five students come from abroad the university of basel seeks top performance in research teaching and service for years it is among the  best universities in the world and in the germanspeaking world it is one of the top ten   university of lausanne the university of lausanne is a higher teaching and research institution composed of seven faculties where approximately  students and  researchers work and study unil is focused on several academic disciplines especially medicine life sciences geosciences environment business humanities and social sciences an emphasis is placed on an interdisciplinary approach with close cooperation between students teaching staff and professors career history executive vice president rd   current acucela inc acucela inc operates as a clinicalstage biotechnology company it discovers and develops novel therapeutics to treat and show the progression of sightthreatening ophthalmic diseases its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration cataracts presbyopia diabetic retinopathy retinitis igmentosa and stargardt disease the company was founded by ryo kubota in april  and is headquartered in seattle wa public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations lukas scheibler is affiliated with acucela inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ news on lukas scheibler news home advertising board and executive moves energy health care hedge funds m  a private equity technology person lukas scheibler ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed lukas scheibler acucela taps scheibler as executive vp of translational medicine september    •  the seattle times  to treat and slow the progression of sightthreatening ophthalmic diseases hired dr lukas scheibler as executive vice president of translational medicine dr scheibler joins acucela  related news feeds acucela inc pharmaceuticals board and executive moves in pharmaceuticals alumni of university of basel email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤